Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $28,720.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock in a transaction dated Tuesday, October 13th. The stock was sold at an average price of $7.18, for a total value of $28,720.00. Following the completion of the transaction, the insider owned 541,493 shares in the company, valued at $3,887,919.74. The trade was a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Monday, October 5th, Zhenyu Xu sold 7,394 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.12, for a total value of $60,039.28.
• On Thursday, August 27th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.91, for a total value of $89,100.00.
• On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total value of $30,080.00.
• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.29, for a total value of $123,930.00.
• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total value of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total value of $69,200.00.

SOPHiA GENETICS Stock Performance

Shares of SOPHiA GENETICS stock traded down $0.56 during midday trading on Friday, hitting $6.73. The company had a trading volume of 915,442 shares, compared to its average volume of 625,793. The stock has a market cap of $564.58 million, a PE ratio of -5.85 and a beta of 0.95. SOPHiA GENETICS SA has a 1-year low of $3.75 and a 1-year high of $8.98. The business’s 50 day simple moving average is $7.96 and its two-hundred day simple moving average is $6.24. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, equities analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on SOPH. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of SOPHiA GENETICS in a research note on Monday, October 12th. BTIG Research boosted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $10.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Dallas Securities Inc. acquired a new stake in SOPHiA GENETICS during the first quarter worth $50,000. Royal Bank of Canada increased its holdings in SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after buying an additional 18,781 shares during the period. AXQ Capital LP acquired a new position in shares of SOPHiA GENETICS in the 2nd quarter valued at $119,000. Silverberg Bernstein Capital Management LLC raised its stake in shares of SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after buying an additional 4,155 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new position in shares of SOPHiA GENETICS during the 2nd quarter worth about $567,000. 31.59% of the stock is owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.